Viridian Therapeutics, Inc.\DE financial data

Symbol
VRDN on Nasdaq
Industry
Services-Medical Laboratories
Location
221 Crescent Street, Suite 103 A, Waltham, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
MIRAGEN THERAPEUTICS, INC. (to 1/15/2021), SIGNAL GENETICS, INC. (to 2/10/2017), SIGNAL GENETICS LLC (to 7/9/2014)
Latest financial report
10-K - Q4 2024 - Mar 3, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.78K % +25.3%
Debt-to-equity 9.61 % -19.1%
Return On Equity -43.4 % +36.6%
Return On Assets -39.6 % +35.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 81.5M shares +27.7%
Common Stock, Shares, Outstanding 81M shares +50%
Entity Public Float 732M USD -28.3%
Common Stock, Value, Issued 810K USD +50%
Weighted Average Number of Shares Outstanding, Basic 66.4M shares +52.1%
Weighted Average Number of Shares Outstanding, Diluted 66.4M shares +52.1%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 61.1M USD -35.7%
Operating Income (Loss) -299M USD -17.5%
Nonoperating Income (Expense) 29.1M USD +74%
Net Income (Loss) Attributable to Parent -270M USD -13.6%
Earnings Per Share, Basic -4.3 USD/shares +16%
Earnings Per Share, Diluted -4.3 USD/shares +16%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash, Cash Equivalents, and Short-term Investments 718M USD +50.3%
Assets, Current 738M USD +51.8%
Property, Plant and Equipment, Net 1.24M USD -26.1%
Operating Lease, Right-of-Use Asset 2.21M USD +32%
Other Assets, Noncurrent 501K USD -17.1%
Assets 742M USD +51.4%
Accounts Payable, Current 2.14M USD -4.29%
Employee-related Liabilities, Current 10.6M USD +1.19%
Accrued Liabilities, Current 45.4M USD +88.5%
Contract with Customer, Liability, Current 288K USD 0%
Liabilities, Current 47.9M USD +79.7%
Contract with Customer, Liability, Noncurrent 284K USD -50.4%
Operating Lease, Liability, Noncurrent 2M USD +100%
Other Liabilities, Noncurrent 2.02M USD +105%
Liabilities 70.8M USD +46.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10K USD -103%
Retained Earnings (Accumulated Deficit) -996M USD -37.2%
Stockholders' Equity Attributable to Parent 672M USD +51.9%
Liabilities and Equity 742M USD +51.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -45.2M USD +27%
Net Cash Provided by (Used in) Financing Activities 177M USD +2058%
Net Cash Provided by (Used in) Investing Activities -143M USD -976%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 81M shares +50%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.2M USD +83.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 99.6M USD -3.14%
Interest Paid, Excluding Capitalized Interest, Operating Activities 452K USD +304%
Deferred Tax Assets, Valuation Allowance 209M USD +33.9%
Deferred Tax Assets, Gross 209M USD +33.9%
Operating Lease, Liability 2.54M USD +38.5%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -270M USD -14%
Lessee, Operating Lease, Liability, to be Paid 3.08M USD +49.6%
Property, Plant and Equipment, Gross 2.5M USD -8.05%
Operating Lease, Liability, Current 513K USD -39.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 747K USD +61%
Lessee, Operating Lease, Liability, to be Paid, Year One 723K USD -24.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 543K USD +139%
Lessee, Operating Lease, Liability, to be Paid, Year Three 613K USD +29.3%
Deferred Tax Assets, Operating Loss Carryforwards 77.4M USD +14.3%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 627K USD +294%
Additional Paid in Capital 1.48B USD +53.9%
Depreciation, Depletion and Amortization 145K USD +38.1%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 42.2M USD -37.3%
Interest Expense 700K USD 0%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%